Invest-NL invests in innovative migraine treatment by Salvia BioElectronics

Solution for patients between a rock and a hard place

In the Netherlands, more than 2 million people suffer from migraines. For a large group, existing therapies do not provide sufficient relief. These people are daily limited in their functioning and work by migraine attacks. Salvia BioElectronics is working on a new, implantable neurostimulation therapy for people with chronic migraine or cluster headaches. The ultra-thin implant stimulates nerves under the skin and helps to prevent or alleviate attacks.

Patients regain control

With this investment, Salvia aims to complete clinical studies and prepare for market launch in Europe, the US, and Australia. The first product, the MySalvia Therapy, gives patients control over their treatment. Using an external portable controller, they can initiate stimulation at a suitable moment or when a migraine attack threatens.

From potential to impact

Migraine costs Dutch society more than €4 billion annually in healthcare costs and productivity loss. Invest-NL invests in Salvia because this technology offers prospects for patients for whom no effective treatment exists.

"The potential impact on quality of life and economic productivity is significant. By investing now, we help Salvia BioElectronics bridge a crucial phase: from promising technology to tangible impact for patients and the healthcare system," says Mats Wassink, investment associate at Invest-NL.

This investment aligns with the broader ambition of the Life Sciences & Health team at Invest-NL: contributing to sustainable healthcare. We do this by funding innovations like Salvia BioElectronics that keep the healthcare system affordable, staffed, and accessible.